TEVA48125-CNS-300049: A multicenter, randomized, Double Blind, placebo controlled, parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of chronic migraine.
Sponsor: Teva Pharmaceutical Industries
Phase of Development: Phase III
Study Duration: 16 weeks
Enrollment Status: Closed
TEVA48125-CNS-300050: A multicenter, randomized, Double Blind, placebo controlled, parallel-group study comparing the efficacy and safety of 2 dose regiments of subcutaneous administration of TEVA-48125 versus placebo for the preventive treatment of episodic migraine.
Sponsor: Teva Pharmaceutical Industries
Phase of Development: Phase III
Study Duration: 16 weeks
Enrollment Status: Closed
TEVA48125-CNS-30051: A multicenter, randomized, double-blind, parallel-group study evaluating the long term safety, tolerability and efficacy of subcutaneous administration of TEVA-48125 for the preventive treatment of migraine.
Sponsor: Teva Pharmaceutical Industries
Phase of Development: Phase III
Study Duration: This is an 18 month rollover study from TEVA48125-CNS-300049 and TEVA48125-CNS-300050
Enrollment Status: Closed
UBR-MD-02: A multicenter, randomized, double blind, placebo controlled, single attack study to evaluate the efficacy, safety and tolerability of oral Ubrogepant in the acute treatment of migraine.
Sponsor: Allergan
Phase of Development: Phase III
Study Duration: Up to 14 days for the screening period prior to randomization, a 60-day period which to treat a single migraine attack, and a 4-week follow up period. (This study can last 1.5-4 months based on the treatment of a single migraine attack).
Enrollment Status: Closed
UBR-MD-04: A multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of oral Ubrogepant in the acute treatment of migraine with or without aura.
Sponsor: Allergan
Phase of Development: Phase III
Study Duration: This is a 52 week rollover study from UBR-MD-01 and UBR-MD-02
Enrollment Status: Closed
Principal Investigator for the above clinical trials: Jessica Heiring, MD
Research Contact: 763-302-4099
MAP
